| 3.085 -0.005 (-0.16%) | 04-24 13:48 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.12 | 1-year : | 4.78 |
| Resists | First : | 3.53 | Second : | 4.09 |
| Pivot price | 3.36  |
|||
| Supports | First : | 2.6 | Second : | 2.17 |
| MAs | MA(5) : | 3.1 |
MA(20) : | 3.33 |
| MA(100) : | 3.52 |
MA(250) : | 3.78 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.8 |
D(3) : | 24.2 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 7.8 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OMER ] has closed above bottom band by 23.3%. Bollinger Bands are 16.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.26 - 3.27 | 3.27 - 3.29 |
| Low: | 3.03 - 3.05 | 3.05 - 3.07 |
| Close: | 3.06 - 3.09 | 3.09 - 3.12 |
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Fri, 19 Apr 2024
Omeros Corporation's (NASDAQ:OMER) 19% loss last week hit both individual investors who own 46% as well as ... - Simply Wall St
Tue, 16 Apr 2024
Omeros (NASDAQ:OMER) Stock Passes Above Two Hundred Day Moving Average of $3.00 - MarketBeat
Wed, 03 Apr 2024
Omeros Corporation's $50M Buyback Plan: A Double-Edged Sword for Stock Stability - TipRanks.com - TipRanks
Tue, 02 Apr 2024
Earnings call: Omeros extends cash runway, reports on clinical progress - Investing.com
Mon, 01 Apr 2024
Omeros: Q4 Earnings Snapshot - Quartz
Wed, 27 Mar 2024
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 - The Bakersfield Californian
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 43.2 (%) |
| Shares Short | 13,290 (K) |
| Shares Short P.Month | 13,820 (K) |
| EPS | -2.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -576.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 75 (M) |
| Levered Free Cash Flow | 96 (M) |
| PE Ratio | -1.11 |
| PEG Ratio | -0.1 |
| Price to Book value | -7.53 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|